Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
AMA Journal of Ethics theme editor Terri Davis, a third-year MD student at West Virginia University School of Medicine, interviewed Ranit Mishori, MD, about how to respond to incidents of suspected human trafficking in health care settings.
Although identical twin-to-twin skin grafting has resulted in excellent survival rates in burn patients, the nature and scope of ethical decision making in monozygotic sibling skin grafting needs further examination.
AMA J Ethics. 2018;20(6):537-545. doi:
10.1001/journalofethics.2018.20.6.cscm2-1806.